By creator to www.businesswire.com
LEE’S SUMMIT, Mo.–(BUSINESS WIRE)–America District Courtroom for District of Delaware has dominated that the patent asserted in CareDx’s patent infringement case in opposition to Eurofins Viracor is invalid. Eurofins Viracor could be very happy that the Courtroom has agreed with its arguments and issued judgment in Eurofins Viracor’s favor on this problem to Eurofins’ critically necessary diagnostic instruments to handle organ rejection threat.
Eurofins Viracor’s choices embody Viracor TRAC® Kidney dd-cfDNA, Viracor TRAC® Coronary heart dd-cfDNA and Viracor TRAC® Lung dd-cfDNA. In associated innovation for transplant sufferers earlier this week, Eurofins Viracor’s affiliate, Transplant Genomics, Inc. (“TGI”), launched OmniGraf™, which mixes the TruGraf® blood gene expression take a look at and Viracor TRAC® donor-derived cell-free DNA assays. For renal transplant recipients, OmniGraf™ Kidney represents the primary diagnostic instrument that mixes cell free DNA and gene expression knowledge. When mixed with TGI’s proprietary know-how and machine studying, the take a look at presents sufferers and clinicians an early and correct evaluation of kidney transplant rejection.
OmniGraf™ is a trademark of Transplant Genomics, Inc.
TruGraf® is a registered trademark of Transplant Genomics, Inc.
Viracor TRAC® is a registered trademark of Eurofins Viracor, LLC
About Viracor
With over 30 years of specialized experience in infectious illness, immunology and allergy testing for immunocompromised and significant sufferers, Viracor Eurofins is dedicated to delivering outcomes to medical professionals, transplant groups, reference laboratories and biopharmaceutical firms sooner, when it issues most. Eurofins Viracor is obsessed with delivering worth to its shoppers by offering well timed, actionable info, by no means dropping sight of the connection between the testing it performs and the sufferers it finally serves.
Eurofins Viracor is a subsidiary of Eurofins Scientific (EUFI.PA), a world chief in bio-analytical testing, and one of many world leaders in genomic providers. For extra info, please go to https://www.eurofins.com/ and https://www.eurofins-viracor.com/.
For extra info, please go to https://www.eurofins-viracor.com/clinical/:
About Eurofins – the worldwide chief in bio-analysis
Eurofins is Testing for Life. With 55,000 workers throughout a community of 900 laboratories in over 50 international locations, Eurofins’ firms provide a portfolio of over 200,000 analytical strategies.
Eurofins Shares are listed on Euronext Paris Inventory Change.
— to www.businesswire.com
